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We examined changes in expression of the candidate plasticity-related gene 15 (CPG15) in 
the dentate gyrus (DG) and hippocampal CA3 region in the pentylenetetrazole (PTZ) kindling 
model and investigated the role of this gene in the phenomenon of mossy fiber sprouting 
(MFS). Experimental rats were divided into the control and PTZ groups. The epileptic model 
was created by intraperitoneal PTZ injection, while control rats were injected with saline. 
At days 3, 7, 14, 28, and 42 after the first PTZ injection, Timm staining was scored in the 
CA3 hippocampal area, and a product of CPG15 (protein CPG15) was labeled in the DG 
stratum granulosum and in the CA3 area using immunohistochemistry. The Timm scores in 
the CA3 region increased gradually from day 3 and were significantly higher than those in 
the control within the subsequent period. The level of CPG15 protein in the DG and CA3 
area decreased gradually until day 14 and returned to the normal level at day 28. The results 
obtained indicate, for the first time, that CPG15 may be involved in the process of MFS. 
Understanding the molecular mechanisms underlying this phenomenon may lead to successful 
therapeutic interventions that limit epileptogenesis.
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INTRODUCTION
Epilepsy is a widespread chronic neurological 
disorder. Although the exact pathogenetic mechanisms 
of this disease remain unclear to a great extent, mossy 
fiber sprouting (MFS) is a pathological phenomenon 
observed in both animal models of temporal lobe 
epilepsy (TLE) and brain sections of epileptic patients 
[1–3]. Most studies supported the hypothesis that 
MFS contributes to increased seizure susceptibility 
by forming recurrent excitatory neuronal circuits. 
However, the mechanisms underlying these structural 
changes are not fully understood.
The hippocampal mossy fibers, axons of dentate 
granule cells, are normally guided to the CA3 area 
of the hippocampal area and form synapses with 
pyramidal cells. However, mossy fibers in the epileptic 
hippocampus abnormally innervate, due to MFS, 
granule cells and the molecular layer, establishing 
hyperexcitable recurrent circuits in the dentate gyrus 
(DG) [4]. Based on recent findings [5–7], MFS can 
be regarded as a result of the disruption of molecular 
mechanisms underlying axonal growth and axonal 
guidance. 
The candidate plasticity-related gene (CPG15) is the 
first isolated one in a screen for activity-regulated genes 
mediating synaptic plasticity in the rat hippocampus 
[8]. This gene encodes a small protein attached to the 
plasma membrane by its glycosylphosphatidylinositol 
(GPI) anchor. Protein CPG15 is a downstream target of 
the classic synaptic plasticity signaling cascade, which 
regulates axonal and dendritic arbor growth, as well as 
synapse maturation and neuronal survival in the CNS [9–
11]. Since mossy fibers are axons of granule cells, it is 
possible that CPG15 is related to MFS in epileptogenesis 
via regulation of the axonal growth and synaptic plasticity.
We investigated the correctness of this hypothesis 
using the pentylenetetrazole (PTZ) kindling model, 
widely adopted as a model of synaptic rearrangement 
and neuronal plasticity in the epileptic brain.
METHODS
Animals and the PTZ Model. One hundred twenty 
adult male Sprague-Dawley rats (Animal Experimental 
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Centre, Central South University, China) weighing 
180 to 220 g were equally divided into control and 
PTZ groups, each containing five subgroups of 12 
rats. The PTZ group received 30 mg/kg PTZ (Sigma, 
USA) i.p. once per day until the rats were kindled or 
sacrificed, while the control rats were injected with 
an equal volume of the solvent (saline). Rats were 
considered kindled when seizure attacks (score ≥ 3) 
occurred after each PTZ injection for five consecutive 
days. At time points of 3, 7, 14, 28, and 42 days, after 
the first PTZ injection, rats were sacrificed under deep 
anesthesia. 
Behavior Monitoring. Rats were observed for 
the occurrence of PTZ-induced seizures for at least 
2 hours within one day before being kindled. The 
convulsive behavior was evaluated as previously 
described [12], using the following estimates: 0, no 
behavioral changes; 1, facial movements, ear and 
whisker twitching; 2, myoclonic convulsions without 
rearing; 3, myoclonic convulsions with rearing; 
4, clonic convulsions with loss of posture, and 5, 
generalized clonicotonic seizures.
Timm Staining. At different time points, the rats 
were deeply anesthetized with 10% chloral hydrate and 
perfused intracardially with 300 ml of saline, followed 
by 200 ml of 0.1 M phosphate buffer (pH 7.2-7.6) 
containing 0.4% sodium sulfide and by 200 ml of 4% 
paraformaldehyde at 4°C. The brains were removed, 
fixed in 4% paraformaldehyde for 24 h, transferred to 
0.1 M phosphate buffer with 30% sucrose, and finally 
cut into 30-µm-thick coronal sections. 
The sections were stained in the dark for 90 min in 
a solution containing 60 ml of 50% gum arabic, 10 ml 
of 2.0 M citrate buffer, 30 ml of 0.5 M hydroquinone, 
and 0.5 ml of 17% silver nitrate. After washing out 
in water, the slides were restained with Nissl solution 
(Beyotime, China). After that, the slides were routinely 
dehydrated, cleaned, and mounted with gum. The 
Timm scores in the inner molecular layer (IML) and in 
the CA3 region were estimated as previously reported 
[13].
Immunohistochemistry. At different time points, 
the rats were deeply anesthetized with 10% chloral 
hydrate and perfused intracardially with 300 ml of 
saline and 200 ml of 4% paraformaldehyde in 0.1 M 
phosphate buffer at 4°C. The brains were removed 
and placed in 4% paraformaldehyde overnight, then 
transferred into 0.1 M phosphate buffer containing 
20% and 30% sucrose. Subsequently, 20-µm-thick 
serial sections were prepared for the analysis. The 
tissue sections were subjected to conventional 
rewarming and heat-induced antigen retrieval in 
10 mM sodium citrate buffer at the boiling point 
for 24 min with supplementation with cool sodium 
citrate buffer every 6 min. Peroxidase and lipids 
were eliminated by an admixture of 1% hydrogen and 
methanol at 4°C for 30 min. After rinsing in 0.01 M 
PBS, the sections were blocked using a 5% goat serum 
reagent at room temperature for 2 h and incubated 
with anti-CPG15 (rabbit anti-rat polyclonal antibody, 
1:50, Santa Cruz, USA) overnight at 4°C. Then, 
immunohistochemistry was performed according to the 
kit protocol (Zhongshan Goldenbridge Tech, China). 
All slices were processed with a Leica DM 5000B 
color-image analysis system (Switzerland) for imaging 
and analysis; the DG and area CA3 were examined.
Statistical Analysis. Numerical data are expressed 
as means ± s.d. Intergroup differences in Timm scores 
were compared using the Mann-Whitney U test, 
while intragroup differences were compared using the 
Kruskal-Wallis H test and then the Nemenyi test for 
pairwise comparisons. Differences among multiple 
groups were assessed by a one-way ANOVA, and 
differences between two groups were evaluated using 
the independent-samples t-test. Differences with 
P < 0.05 were considered significant. All statistical 
analyses were performed using the Statistical package 
for social sciences (SPSS), version 17.0.
RESULTS
Behavioral Outcomes. With the exception of three 
rats that died after the development of persistent 
generalized clonic-tonic seizures within days 3 to 14 
and one rat with no kindling developed, the remaining 
PTZ-treated rats manifested seizure activity of 
different degrees after continuous PTZ injections 
within days 21–28 (average, 22.7 ± 2.0 days). The PTZ-
induced seizure activity usually occurred 5–10 min 
after injection and lasted 5 to 30 min. No epileptiform 
activity was observed behaviorally in control rats.
Severity of MFS in the CA3 Area Correlates with 
Evolution of Seizure Behavior. In control rats, there 
was no significant difference in the Timm scores in 
area CA3 (P > 0.05) (Fig. 3). There were significant 
differences in these scores in the above area at each 
time point between the PTZ and control groups 
(P < 0.05) (Figs. 1A and 3). The degrees of MFS in 
the CA3 were consistent with the grades of seizures in 
the PTZ group and reached the peak at day 28. On the 
other hand, the Timm scores in the IML were 0 or 1 
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F i g. 1. Timm staining in the CA3 area of control and PTZ-
treated rats. The intensity of Timm granules increased with 
the development of kindling in area CA3 in the PTZ group. 
Р и с. 1. Забарвлення, за Тіммом, у зоні CA3 контрольних 
щурів та щурів, котрим ін’єкували пентилентетразол. 
Contr.
14
A
Control
PTZ 28
Control
PTZ 28
PTZ 14
PTZ 42 days
PTZ 14
PTZ 42 days
B
28 days
21
F i g.2. Expression of CPG15 in the CA3 region of the 
hippocampus (A) and dentate gyrus (B) visualized by 
immunohistochemistry in the control group and at different 
time points in the PTZ group.
Р и с. 2. Експресія протеїну CPG15 у зоні CA3 гіпокампа 
(А) та зубчастій звивині (В) у контрольній групі та гру-
пі пентилентетразолового кіндлінгу в різні моменти 
часу (візуалізовано за допомогою імуногістохімічної 
методики). 
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throughout the experiment in the PTZ group, with no 
difference with respect to the control group (data not 
shown).
Expression of Protein CPG15 Is Significantly 
Down-Regulated during PTZ Kindling Progression. 
The expression of CPG15 was mainly observed in 
the neuronal membranes within different regions of 
the hippocampus. Compared with the control group, 
the expression of CPG15 in pyramidal cells of the 
CA3 region and in hilar neurons of the DG were 
significantly down-regulated (P < 0. 05) in the PTZ 
group (Fig. 1A, B and Fig. 3A, B; Table 1). This 
expression decreased gradually from day 3 to day 14 
and returned to the control level at day 28, but down-
regulated again at day 42. No obvious distinction was 
observed in both CA3 and DG areas among different 
time points in the control group (Table 2).
DISCUSSION
We examined the potential role of protein CPG15 in 
MFS using the PTZ kindling rat model. We found 
that MFS preceded the appearance of spontaneous 
recurrent seizures (SRSs) in such rats. The expression 
of protein CPG15 is in agreement with the progression 
of MFS.
The occurrence and development of epilepsy are 
usually associated with neuronal loss [14], MFS [15], 
and synaptic reorganization in the hippocampus. These 
alterations, especially MFS, are highly associated with 
the appearance of SRSs in humans and in epileptic 
animal models.
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F i g. 3. Quantitative analysis of CPG15 protein expression in the 
CA3 area (A) and dental gyrus (B). Vertical scale) Arbitrary units; 
horizontal scale) days after the first PTZ injection. Open and 
filled columns, control and PTZ groups, respectively. The data are 
expressed as means ± s.d.
Р и с. 3. Кількісний аналіз експресії протеїну CPG15 у зоні CA3 
(А) та зубчастій звивині (В).
T a b l e 1. Quantitative analysis of CPG15 expression in the PTZ group. 
Т а б л и ц я 1. Кількісний аналіз експресії CPG15 у групі ПТЗ 
Group Time points, days DG CA3
PTZ 3 0.045±0.008* 0.103±0.022
7 0.026±0.004* 0.087±0.007
14 0.023±0.003* 0.063±0.004*
28 0.042±0.007 0.106±0.008
42 0.027±0.003* 0.072±0.009*
Footnote. The data are expressed as means ± s.d.; differences from the control, *P < 0.05
T a b l e 2. Quantitative analysis of CPG15 expression in the control group. 
Т а б л и ц я 2. Кількісний аналіз експресії CPG15 у групі контролю
Group Time points, days DG CA3
Control 3 0.066±0.006 0.118±0.009
7 0.060±0.011 0.118±0.010
14 0.051±0.008 0.101±0.016
28 0.055±0.002 0.109±0.0003
42 0.056±0.009 0.100±0.008
Footnote. Designations are similar to those in Table 1.
* *
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Our study demonstrated that the degree of aberrant 
MFS is consistent with the severity of seizures, and 
initiation of MFS precedes the occurrence of SRS. 
However, there are also some reservations. As was 
found in several other studies, MFS was not associated 
with the progression of spontaneous seizures [16, 
17]. In our study, however, MFS could be observed 
on day 3, i.e., before the appearance of clear SRSs, 
indicating that MFS is rather likely to be the cause of 
such seizures.
CPG15 is a gene highly expressed in the nervous 
system; in the adult age, it is restricted to the region 
endowed with a high degree of plasticity, namely in 
the hippocampus. The expression of CPG15 protein 
was down-regulated gradually in the CA3 area and 
DG region in the PTZ group. The spatial and temporal 
distribution consistencies of CPG15 and Timm 
staining supported the existence of a correlation 
between expression of this protein and the process of 
MFS. This finding, thus, suggests that CPG15 and its 
protein product may be significantly involved in the 
synaptic specificity of MFS.
Neurotrophins form a group of factors involved in 
nerve cell survival, proliferation, differentiation, and 
synaptic functions. These factors are generated by 
neural tissues, muscles, and astrocytes. Some studies 
have shown that neurotrophins are highly associated 
with epileptogenesis and the MFS phenomenon [18–
21]. In other studies, it was proposed that epilepsy-
related neural activity is the trigger of MFS. Protein 
CPG15 is a novel neurotrophin; it is a downstream 
target of the classic synaptic plasticity signaling 
cascade, involving the MAPK, CaMK, and CREB 
[22]. Both in vivo and in vitro studies [23] have 
demonstrated that CPG15 may represent a common 
effector of neurotrophins with respect to the neuronal 
activity function. Neural activity and neurotrophins 
induce synaptic remodeling, in particular, by altering 
the gene expression. Based on previous research, 
CPG15 can regulate axonal and dendritic arbor 
growth, as well as maturation of synapses and survival 
of neurons in the CNS. However, the mechanisms 
underlying the relationship between CPG15 and MFS 
were not investigated in our study.
In vivo studies [24] demonstrated that CPG15 
protein must be attached to the plasma membrane by 
its GPI anchor to manifest its neurotrophic effects. 
GPI-anchored molecules encompass a large group 
of proteins of great functional diversity, including 
many axon-guidance molecules, such as ephrins and 
NCAM. These molecules are able, through contact 
attraction or repulsion, to regulate axonal pathfinding 
and growth. So, CPG15, being a GPI-anchored 
molecule, can, through contacts with axons, trigger a 
series of molecular events providing regulation of the 
axonal growth, pathfinding, and synaptic plasticity. 
Considering that CPG15 affects and regulates the 
above events, it should be qualified as an activity-
induced signaling molecule capable of communicating 
between neighboring cells [25]. The receptor of 
CPG15 and the downstream of the above conduction 
pathway remain, however, unknown.
In conclusion, our study demonstrated that MFS 
is not the outcome of the SRS initiation. Our results 
indicate, for the first time, that expression of CPG15 
may be involved in the development of MFS and 
synaptic reorganization. A throughout understanding 
of the molecular mechanisms underlying MFS may 
lead to therapeutic interventions that protect the brain 
from spontaneous seizures.
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Р е з ю м е
Ми досліджували зміни експресії продукту гена CPG15 
у зубчастій звивині (ЗЗ) та зоні CA3 гіпокампа в моделі 
пентилентетразолового (ПТЗ-) кіндлінгу та можливу роль 
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цього гена у феномені спрутингу моховитих волокон 
(СМВ). Піддослідні щури були поділені на групи контро-
лю та ПТЗ-кіндлінгу. Модель епілепсії створювали за допо-
могою внутрішньоочеревинних ін’єкцій пентилентетразолу 
(ПТЗ); контрольним щурам ін’єкували фізіологічний 
розчин. На третю, сьому, 14-ту, 28-му та 42-гу добу після 
першої ін’єкції ПТЗ оцінювали забарвлення, за Тіммом, у 
зоні CA3. Локалізацію протеїну CPG15 у stratum granulo-
sum ЗЗ та зоні CA3 гіпокампа визначали з використанням 
імуногістохімічної методики. Інтенсивність забарвлення, за 
Тіммом, у зоні CA3 поступово збільшувалася починаючи з 
третьої доби та була вірогідно вищою, ніж така в контролі, 
протягом усього наступного періоду. Рівень протеїну CPG15 
у ЗЗ та полі CA3 поступово зменшувався до 14-ї доби та 
повертався до нормальних значень на 28-му добу. Отримані 
результати вперше вказують на те, що CPG15 може бути 
залученим у процес СМВ. Зрозуміння молекулярних ме-
ханізмів, на яких базується цей феномен, може призвес-
ти до розробки успішних терапевтичних заходів, кот- 
рі обмежували б епілептогенез. 
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